

May 15, 2026

To,
BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai 400001

Scrip code: 543916

Sub.: Outcome of the Board Meeting pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 held on Friday, May 15, 2026

Dear Sir/Madam,

With reference to the captioned subject and in compliance with the regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is to inform you that the Board of Directors of the Company at its Meeting held today i.e. Friday, May 15, 2026, inter-alia have considered and approved;

1. Audited Financial results for the half and financial year ended on March 31, 2026, in this regard, please find enclosed herewith:

- (a) Audited Financial Results (standalone and consolidated) of the Company for the half and financial year ended on March 31, 2026.
- (b) Auditor's Report in respect of the Audited Financial Results (standalone and consolidated) of the Company for the financial year ended March 31, 2026.

These are also being made available on the website of the Company at www.hemantsurgical.com

Pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that the Statutory Auditors of the Company have issued their audit reports with unmodified opinion for the half and financial year ended on March 31, 2026.

The Meeting was commenced at 02.30 p.m. and concluded at 04.05 p.m.

Please take the same on your records and suitably disseminated at all concerned.

Thanking you,

Yours faithfully,
For Hemant Surgical Industries Limited

Hanskumar Shamji Shah
Managing Director
DIN: 00215972
Email id: hanskumar@hemantsurgical.com

502,5th Floor, Ecstasy, JSD Road, City of Joy Commercial, Mulund (W), Mumbai-400 080.
Tel. : +91-22-2591 2747

Email: info@hemantsurgical.com, sales@hemantsurgical.com, Web : www.hemantsurgical.com
CIN: L33110MH1989PLC051133

Independent Auditor’s Report on the Half Yearly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Members of Hemant Surgical Industries Limited

Report on the Audit of the Standalone Financial Statements:

Opinion

We have audited the accompanying Half Yearly and Year to date Standalone Financial Statements of **Hemant Surgical Industries Limited (“the Company”)** for the half year and year ended March 31, 2026 (“the Statement”), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (hereinafter referred to as “Listing regulations”).

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Standalone Financial Statements give the information required by the Listing Regulations and the Companies Act, 2013 (“the Act”) in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with the Companies (Accounting Standards) Rules, 2015, as amended, (“AS”) and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, the profit and its cash flows for the half year ended March 31, 2026 and year ended on that date.

Basis for opinion

We conducted our audit of the Standalone Financial Statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the Standalone Financial Statements under the provisions of the Act and the Rules made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI’s Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Standalone Financial Statements.

Information Other than the Standalone Financial Statements and Auditor’s Report thereon

The Company’s Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board’s Report including Annexure to Board’s Report, Business Responsibility Report, Corporate Governance and Shareholder’s Information, but does not include the Consolidated Financial Statements, Financial Statements and our auditor’s report thereon.

Our opinion on the Standalone Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Standalone Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Standalone Financial Statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Management’s Responsibility for the Standalone Financial Statements

The Company’s Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these Standalone Financial Statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the Regulation 33 of the Listing Regulations and Accounting Standards and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of

the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Standalone Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Statements, including the disclosures, and whether the Standalone Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Standalone Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Standalone

Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Standalone Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

For A D V & Associates
Chartered Accountants
FRN: 128045W

Pratik
Kabra

Digitally signed
by Pratik Kabra
Date: 2026.05.15
15:41:19 +05'30'

Pratik Kabra
Partner

M. No.: 611401

UDIN: 26611401DPKACF4785

Place: Mumbai

Date: 15th May, 2026

HEMANT SURGICAL INDUSTRIES LIMITED

CIN :L33110MH1989PLC0511333

ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080
Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747
STANDALONE BALANCE SHEET AS AT MARCH 31, 2026

(₹ in Lakhs)

Particulars	As at March 31, 2026 (Audited)	As at March 31, 2025 (Audited)
I Equity & Liabilities		
1.Shareholders funds:		
a. Share Capital	1,303.84	1,044.00
b. Reserves and Surplus	11,412.67	5,255.03
c. Money Received against Share Warrants	1,033.86	-
2.Non-Current liabilities:		
a. Long-Term Borrowings	288.36	2,333.22
b. Deferred Tax Liabilities(Net)	-	-
c. Long Term Provisions	63.99	54.79
3.Current Liabilities:		
a. Short Term Borrowings	4,678.12	751.11
b. Trade Payables		
i. Micro enterprises and small enterprises	226.39	264.87
ii. Other than micro enterprises and small enterprises.	6,894.13	3,615.88
c. Other Current Liabilities	1,125.77	1,060.88
d. Short Term Provisions	373.61	384.55
Total	27,400.73	14,764.34
II Assets		
1.Non-Current Assets:		
a. Property, Plant & Equipment and Intangible Assets	5,339.64	3,986.62
b. Capital Work in progress	-	1,188.15
c. Non-Current Investments	20.25	20.90
d. Deferred Tax assets(net)	78.48	16.34
e. Long Term Loans & Advances	2,259.02	502.62
f. Other Non Current Assets	500.86	249.22
2.Current Assets:		
a. Current Investments		
b. Inventories	5,865.29	4,247.51
c. Trade Receivables	6,724.81	2,031.15
d. Cash and Cash Equivalents	4,383.11	945.69
e. Short Term Loans and Advances	908.79	767.38
f. Other Current Assets	1,320.48	808.76
Total	27,400.73	14,764.34

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED

Hans Kumar

Hanskumar Shamji Shah
Managing Director
DIN - 00215972
Place : Mumbai
Date: 15th May, 2026



HEMANT SURGICAL INDUSTRIES LIMITED

CIN : L33110MH1989PLC0511333

ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080

Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747

STANDALONE STATEMENT OF PROFIT AND LOSS FOR THE HALF YEAR AND YEAR ENDED AS ON MARCH 31, 2026

(₹ In lakhs except EPS)

Particulars	Half Year Ended			Year Ended	
	March 31, 2026	September 30, 2025	March 31, 2025	March 31, 2026	March 31, 2025
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I. Revenue from Operations	16,672.65	6,426.06	5765.60	23,098.71	10,652.66
II. Other Incomes	339.30	233.43	270.40	572.73	496.86
III. Total Revenue (a)	17,011.95	6,659.49	6,036.01	23,671.44	11,149.53
IV. Expenses					
1. Cost of Raw Materials Consumed	14,551.27	4,188.19	5,236.36	18,739.46	9,391.18
2. Change in Inventories	(1,404.65)	442.08	(1,123.98)	(962.56)	(1,853.83)
3. Employee Benefits Expenses	511.95	484.91	506.63	996.85	932.62
4. Finance Costs	201.18	195.33	143.41	396.51	220.43
5. Depreciation	78.89	73.29	73.90	152.18	142.49
6. Other Expenses	1,432.62	553.37	591.96	1,986.00	1,261.09
V. Total Expenses (b)	15,371.26	5,937.17	5,428.27	21,308.43	10,093.99
V. Profit before Exceptional and Extraordinary Items and Tax	1,640.69	722.32	607.73	2,363.01	1,055.53
VI. Exceptional Items	-	-	-	-	-
VII. Profit Before Extraordinary items and Tax	1,640.69	722.32	607.73	2,363.01	1,055.53
VIII. Extraordinary Items	-	-	-	-	-
IX. Profit before tax	1,640.69	722.32	607.73	2,363.01	1,055.53
X. Tax Expense					
a. Current Tax	343.72	143.32	164.17	487.04	276.88
b. Earlier Year Tax	(61.71)	-	(11.92)	(61.71)	(11.92)
c. Deferred Tax Expenses/(Income)	75.86	38.48	(39.50)	114.34	(22.63)
XI. Profit for the period from Continuing Operations	1,282.81	540.53	494.98	1,823.34	813.21
XII. Profit from Discontinuing Operations	-	-	-	-	-
XIII. Tax Expense of Discontinuing Operations	-	-	-	-	-
XIV. Profit from Discontinuing Operations after Tax	-	-	-	-	-
XV. Profit for the period	1,282.81	540.53	494.98	1,823.34	813.21
XVI. Earning per Equity Share of face value of Rs 10 each					
(a) Basic EPS	10.85	5.09	4.74	15.42	7.79
(b) Diluted EPS	10.54	5.05	4.74	14.98	7.79

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED

Hans Kumar

Hans Kumar Shamji Shah
Managing Director
DIN - 00215972
Place : Mumbai
Date: 15th May, 2026



HEMANT SURGICAL INDUSTRIES LIMITED

CIN :L33110MH1989PLC0511333

ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080


Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747

STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED ON MARCH 31, 2026

(₹ in Lakhs)

Particulars		For the year ended March 31, 2026 (Audited)	For the year ended March 31, 2025 (Audited)
A	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit before tax as per Profit And Loss A/c	2,363.01	1,055.53
	Adjustments for:		
	Depreciation & Amortisation Expense	152.18	142.49
	Interest Income	(166.56)	(59.23)
	Profit on Sale of Fixed Assets	(104.00)	(17.81)
	Finance Cost	396.51	214.89
	Provision for Gratuity	12.12	22.27
	Loss By Fire of Plant and Machinery	-	116.53
	Operating Profit Before Working Capital Changes	2,653.25	1,474.68
	Changes in Working Capital		
	Adjusted for (Increase)/ Decrease in:		
	Trade Payables	3,239.78	1,420.11
	Other Current Liabilities	64.89	11.08
	Short term provision	-	16.06
	Inventories	(1,617.78)	(2,142.47)
	Trade Receivables	(4,693.66)	142.51
	Loans and Advances	(1,897.82)	244.49
	Other current assets	(511.72)	(514.30)
	Cash Generated From Operations	(5,416.32)	(822.52)
	Appropriation of Profit		
	Net Income Tax paid/ refunded	(439.20)	(192.71)
	Net Cash Flow from/(used in) Operating Activities: (A)	(3,202.27)	459.45
B	Cash Flow From Investing Activities:		
	Purchases of Fixed Assets (including capital work in progress)	(164.86)	(3,768.37)
	Sales of Fixed Assets	(48.18)	235.11
	Loss By fire of Plant and Machinery	-	(116.53)
	Interest Income	166.56	59.23
	Net Increase/(Decrease) in Non Current Investment	0.65	471.92
	Net Increase/(Decrease) in Other Non Current Assets	(251.64)	93.67
	Net Cash Flow from/(used in) Investing Activities: (B)	(297.46)	(3,024.97)
	Cash Flow from Financing Activities:		
	Net Increase/(Decrease) in Long Term Borrowings	(2,044.86)	1,979.01
	Short term Borrowings	3,927.01	430.03
	Proceeds from issue of share (Net of Issue Expenses)	5,451.51	-
	Finance Cost	(396.51)	(214.89)
	Net Cash Flow from/(used in) Financing Activities: (C)	6,937.15	2,194.15
C	Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	3,437.42	(371.37)
	Cash & Cash Equivalents As At Beginning of the Year	945.69	1,317.06
	Cash & Cash Equivalents as at end of the year	4,383.11	945.69

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED


Hanskumar Shamji Shah
Managing Director
DIN - 00215972
Place : Mumbai
Date: 15th May, 2026



HEMANT SURGICAL INDUSTRIES LIMITED
CIN : L33110MH1989PLC0511333

ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080

Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-2591289/022-25912747

NOTES TO STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED March 31, 2026

1	The above Audited standalone financial results of Hemant Surgical Industries Limited ("the Company") for the half year ended March 31, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 15, 2026.
2	The above Audited standalone financial results of the Company for the half year ended March 31, 2026, are prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25 - Interim Financial Reporting, prescribed under section 133 of the Companies Act, 2013 and other recognised accounting principles generally accepted in India.
3	As per MCA Notification dated February 16, 2015 Companies whose shares are listed on SME Platform of exchanges as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2009, are exempted from the compulsory requirement of adoption of IND-AS.
4	In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Audited standalone financial results for the half year ended March 31, 2026 has been reviewed by Statutory Auditors of the Company.
5	These financial statements are prepared in accordance with Indian Generally Accepted Accounting Principles (IGAAP) under the historical cost convention on the accrual basis. IGAAP comprises mandatory accounting standards as prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the relevant amendment rules thereafter.
6	The Company is operating in a Single Segment. Hence, the above financial results are based on single segment only.
7	Earning Per share is calculated on the weighted average of the share capital received by the company. Half yearly EPS is not annualised.
8	During the half year, the Company has raised an amount of ₹ 6,152.71 Lakhs by way of issue of the of 25,98,400 equity shares of Rs 10/- each at a price of ₹ 197 (including premium of ₹ 187 per equity share) and 20,99,200 warrants having face value of Rs. 10/- each at a price of ₹ 197 per warrant (on receipt of 25% of the ₹ 197 i.e. ₹ 49.25 per warrant), each warrant convertible into one equity share on payment of balance amount 147.75 i.e. 75% of ₹ 197 within a period of 18 months from the date allotment. The utilisation of proceeds of the aforesaid issues during the half year ended March 31, 2026, is as below, as required in terms of provisions of regulation 32 of the SEBI LODR, as amended.

(₹ in Lakhs)

Object of the Issue	Amount Allocated for the Object	Amount Utilised	Balance Available in Bank	Amount yet to be receivable form Warrants Holder
Capital expenditure towards development/setting up of new facilities and expansion of existing manufacturing facilities including strategic acquisition/investment	5,000.00	409.36	1,489.07	3,101.57
Augment working capital needs of the Company and its Subsidiaries	1,500.00	1,500.00		
Repayment of debt	1,700.00	1,700.00		
For general corporate purposes	1,054.27	1,054.27		
Total	9,254.27	4,663.63		

Out of the total proceeds of ₹6,152.71 Lakhs, the Company has utilised ₹4,663.63 Lakhs for the intended purposes. The balance amount of ₹ 1,489.07 Lakhs is currently lying in the Company's bank account. In Addition to above the company would going to receive ₹3,101.57 Lakhs at the time of conversion of the warrants.

9	On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed the same & there is no material impact of these changes and to the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. The Company continues to monitor the finalisation of Central/ State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect (if any) on the basis of such developments as needed.
10	The figures for the second half of the financial year ended 31st March 2026 have been arrived at by deducting the unaudited financial results for the half year ended September 30, 2025 from the audited results for the full year ended 31st March 2026. These figures are not subjected to separate audit or limited review.
11	The figures of the previous period have been re-grouped or rearranged, wherever considered necessary.

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED

Hans Kumar Shamji Shah
Hans Kumar Shamji Shah
Managing Director
DIN - 00215972
Place: Mumbai
Date: 15th May, 2026



Independent Auditor’s Report on the Half Yearly and Year to Date Audited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Members of Hemant Surgical Industries Limited

Report on the Audit of the Consolidated Financial Statements:

Opinion

We have audited the accompanying Half Yearly and Year to date Consolidated Financial Statements of **Hemant Surgical Industries Limited (“the Company”)** for the half year and year ended March 31, 2026 (“the Statement”), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (hereinafter referred to as “Listing regulations”).

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Consolidated Financial Statements give the information required by the Listing Regulations and the Companies Act, 2013 (“the Act”) in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with the Companies (Accounting Standards) Rules, 2015, as amended, (“AS”) and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, the profit and its cash flows for the half year ended March 31, 2026 and year ended on that date.

Basis for opinion

We conducted our audit of the Consolidated Financial Statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the Consolidated Financial Statements under the provisions of the Act and the Rules made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI’s Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Consolidated Financial Statements.

Information Other than the Consolidated Financial Statements and Auditor’s Report thereon

The Company’s Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board’s Report including Annexure to Board’s Report, Business Responsibility Report, Corporate Governance and Shareholder’s Information, but does not include the Consolidated Financial Statements, Financial Statements and our auditor’s report thereon.

Our opinion on the Consolidated Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Consolidated Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Consolidated Financial Statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Management’s Responsibility for the Consolidated Financial Statements

The Company’s Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these Consolidated Financial Statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the with the Regulation 33 of the Listing Regulations and Accounting Standards and other accounting principles generally accepted in India. This responsibility also includes

maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Consolidated Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Statements, including the disclosures, and whether the Consolidated Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Consolidated Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of

our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Consolidated Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matter

This Statement includes the results of the Following entity:

- a. Solar Opto Medics Private Limited

We have reviewed the financial statements of the subsidiaries included in the consolidated financial statements; whose financial statements include total revenues of Rs.46.38 Lakhs for the half year ended on that date. The review of these financial statements has been carried out by us, and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of the subsidiary, is based on our review of such financial statements conducted by us.

For A D V & Associates
Chartered Accountants
FRN: 128045W

Pratik Digitally signed
by Pratik Kabra
Date: 2026.05.15
15:40:15 +05'30'
Kabra

Pratik Kabra
Partner
M. No.: 611401
UDIN: 26611401RUSKII6968
Place: Mumbai
Date: 15th May, 2026

HEMANT SURGICAL INDUSTRIES LIMITED

CIN :L33110MH1989PLC0511333

ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080

Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747

CONSOLIDATED BALANCE SHEET AS AT MARCH 31, 2026

(₹ in Lakhs)

Particulars	As at March 31, 2026 (Audited)	As at March 31, 2025 (Audited)
I Equity & Liabilities		
1.Shareholders funds:		
a. Share Capital	1,303.84	1,044.00
b. Reserves and Surplus	11,426.71	5,273.31
c. Money Received against Share Warrants	1,033.86	-
2. Non-Current liabilities:		
a. Long-Term Borrowings	288.36	2,333.22
b. Deferred Tax Liabilities(Net)	-	-
c. Long Term Provisions	63.99	54.79
3.Current Liabilities:		
a. Short Term Borrowings	4,678.12	769.77
b. Trade Payables		
i. Micro enterprises and small enterprises	226.39	264.87
ii. Other than micro enterprises and small enterprises.	6,904.72	3,633.42
c. Other Current Liabilities	1,126.52	1,072.94
d. Short Term Provisions	373.61	384.55
Total	27,426.11	14,830.88
II Assets		
1. Non-Current Assets:		
a. Property, Plant & Equipment and Intangible Assets	5,344.50	3,992.86
b. Capital Work in progress	-	1,188.15
c. Non-Current Investments	-	0.65
d. Deferred Tax assets(net)	78.59	16.34
e. Long Term Loans & Advances	2,260.53	504.13
f. Other Non Current Assets	500.86	249.22
2.Current Assets:		
a. Current Investments		
b. Inventories	5,904.98	4,313.63
c. Trade Receivables	6,735.03	2,038.22
d. Cash and Cash Equivalents	4,383.65	954.69
e. Short Term Loans and Advances	896.98	763.72
f. Other Current Assets	1,320.98	809.26
Total	27,426.11	14,830.88

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED

Hans Kumar

Hans Kumar Shamji Shah
Managing Director
DIN - 00215972
Place : Mumbai
Date: 15th May, 2026



HEMANT SURGICAL INDUSTRIES LIMITED

CIN : L33110MH1989PLC0511333

ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080


Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747

CONSOLIDATED STATEMENT OF PROFIT & LOSS FOR THE HALF YEAR AND YEAR ENDED AS ON MARCH 31, 2026

(₹ in Lakhs)

Particulars	Half Year Ended			Year Ended	
	31/03/2026	30/09/2025	31/03/2025	31/03/2026	31/03/2025
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I. Revenue from Operations	16,718.65	6,462.01	5776.63	23,180.66	10,663.69
II. Other Incomes	352.96	233.43	271.20	586.39	512.04
III. Total Revenue (a)	17,071.61	6,695.43	6,047.83	23,767.05	11,175.73
IV. Expenses					
1. Cost of Raw Materials Consumed	14,592.80	4,198.60	5,256.51	18,791.41	9,425.71
2. Change in Inventories	(1,380.65)	444.51	(1,125.44)	(936.14)	(1,855.29)
3. Employee Benefits Expenses	511.97	497.12	507.62	1,009.09	933.61
4. Finance Costs	201.24	195.33	143.39	396.57	220.41
5. Depreciation	79.58	73.97	73.96	153.55	142.56
6. Other Expenses	1,437.62	556.29	593.00	1,993.91	1,262.14
V. Total Expenses (b)	15,442.57	5,965.83	5,449.04	21,408.40	10,129.14
V. Profit before Exceptional and Extraordinary Items and Tax	1,629.04	729.61	598.79	2,358.65	1,046.59
VI. Exceptional Items	-	-	-	-	-
VII. Profit Before Extraordinary items and Tax	1,629.04	729.61	598.79	2,358.65	1,046.59
VIII. Extraordinary Items	-	-	-	-	-
IX. Profit before tax	1,629.04	729.61	598.79	2,358.65	1,046.59
X. Tax Expense					
a. Current Tax	341.83	145.21	164.17	487.04	276.88
b. Earlier Year Tax	(61.71)	-	(11.92)	(61.71)	(11.92)
c. Deferred Tax Expenses/(Income)	75.80	38.42	(39.33)	114.22	(22.47)
XI. Profit for the period from Continuing Operations	1,273.12	545.98	485.87	1,819.10	804.10
XII. Profit from Discontinuing Operations	-	-	-	-	-
XIII. Tax Expense of Discontinuing Operations	-	-	-	-	-
XIV. Profit from Discontinuing Operations after Tax	-	-	-	-	-
XV. Profit for the period	1,273.12	545.98	485.87	1,819.10	804.10
XVI. Earning per Equity Share of face value of Rs 10 each					
(a) Basic EPS	10.24	5.15	4.65	15.39	7.70
(b) Diluted EPS	9.84	5.10	4.65	14.94	7.70

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED



Hanskumar Shamji Shah
Managing Director
DIN - 00215972
Place : Mumbai
Date: 15th May, 2026



HEMANT SURGICAL INDUSTRIES LIMITED

CIN :L33110MH1989PLC0511333

ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080

Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747

CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED ON MARCH 31, 2026

(₹ In lakhs)

Particulars		For the year ended March 31, 2026 (Audited)	For the year ended March 31, 2025 (Audited)
A	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit before tax as per Profit And Loss A/c	2,358.65	1046.59
	Adjustments for:		
	Depreciation & Amortisation Expense	153.55	142.56
	Interest Income	(166.56)	(59.16)
	Profit on Sale of Fixed Assets	(104.00)	(17.81)
	Finance Cost	396.57	214.87
	Provision for Gratuity	12.12	22.27
	Loss By Fire of Plant and Machinery	-	116.53
	Operating Profit Before Working Capital Changes	2,650.33	1,465.85
	Changes in Working Capital		
	Adjusted for (Increase)/ Decrease in:		
	Trade Payables	3,233.22	1436.22
	Other Current Liabilities	53.18	18.29
	Short term provision	-	5.97
	Inventories	(1,591.35)	(2,143.93)
	Trade Receivables	(4,696.81)	139.56
	Loans and Advances	(1,901.82)	248.14
	Other current assets	(511.72)	(514.30)
	Cash Generated From Operations	(5,415.30)	(810.05)
	Appropriation of Profit		
	Net Income Tax paid/ refunded	(439.20)	(192.71)
	Net Cash Flow from/(used in) Operating Activities: (A)	(3,204.17)	463.10
B	Cash Flow From Investing Activities:		
	Net (Purchases)/Sales of Fixed Assets (including capital work in progress)	(164.86)	(3,757.34)
	Sales of Fixed Assets (including capital work in progress)	(48.18)	224.08
	Loss By fire of Plant and Machinery	-	(116.53)
	Interest Income	166.56	59.16
	Net Increase/(Decrease) in Non Current Investment	0.65	347.36
	Net Increase/(Decrease) in Other Non Current Assets	(251.64)	91.09
	Net Cash Flow from/(used in) Investing Activities: (B)	(297.46)	(3,152.18)
	Cash Flow from Financing Activities:		
	Net Increase/(Decrease) in Long Term Borrowings	(2,051.36)	1979.01
	Net Increase/(Decrease) in Short Term Borrowings	3,927.01	420.94
	Proceeds from issue of share (Net of Issue Expenses)	5,451.51	-
	Finance Cost	(396.57)	(214.87)
	Net Cash Flow from/(used in) Financing Activities (C)	6,930.59	2,185.08
C	Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	3,428.96	(504.00)
	Cash & Cash Equivalents As At Beginning of the Year	954.69	1334.13
	Cash & Cash Equivalents As At End of the Year	4,383.65	954.69

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED

Hans Kumar
Hans Kumar Shamji Shah
Managing Director
DIN - 00215972
Place : Mumbai
Date: 15th May, 2026



HEMANT SURGICAL INDUSTRIES LIMITED

CIN : L33110MH1989PLC0511333

ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080

Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747

NOTES TO CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR AND YEAR ENDED ON MARCH 31, 2026

1	The above Audited consolidated financial results of Hemant Surgical Industries Limited ("the Company") for the half year ended March 31, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 15, 2026
2	The above Audited consolidated financial results of the Company for the half year ended March 31, 2026, are prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25 - Interim Financial Reporting, prescribed under section 133 of the Companies Act, 2013 and other recognised accounting principles generally accepted in India.
3	As per MCA Notification dated February 16, 2015 Companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2009, are exempted from the compulsory requirement of adoption of IND-AS.
4	In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Audited consolidated financial results for the half year ended March 31, 2026 has been reviewed by Statutory Auditors of the Company.
5	These financial statements are prepared in accordance with Indian Generally Accepted Accounting Principles (IGAAP) under the historical cost convention on the accrual basis. IGAAP comprises mandatory accounting standards as prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the relevant amendment rules thereafter.
6	The Company is operating in a Single Segment. Hence, the above financial results are based on single segment only.
7	Earning Per share is calculated on the weighted average of the share capital received by the company. Half yearly EPS is not annualised.
8	The consolidated Audited financial results comprise the financial statements of the Company and its wholly owned subsidiary i.e. Solar Opto Medics Private Limited.
9	During the half year, the Company has raised an amount of ₹6,152.71 Lakhs by way of issue of the of 25,98,400 equity shares of Rs 10/- each at a price of ₹197 (including premium of ₹187 per equity share) and 20,99,200 warrants having face value of Rs. 10/- each at a price of ₹ 197 per warrant (on receipt 25% of the ₹ 197 i.e. ₹ 49.25 per warrant), each warrant convertible into one equity share on payment of balance amount 147.75 i.e. 75% of ₹ 197 within a period of 18 months from the date of allotment. Utilisation of proceeds of the aforesaid issues during the half year ended March 31, 2026, is as below, as required in terms of provisions of regulation 32 of the SEBI LODR, as amended:

(₹ in Lakhs)

Object of the Issue	Amount Allocated for the Object	Amount Utilised	Balance Available in Bank	Amount yet to be receivable form Warrants Holder
Capital expenditure towards development/setting up of new facilities and expansion of existing manufacturing facilities including strategic acquisition/investment	5,000.00	409.36	1,489.07	3,101.57
Augment working capital needs of the Company and its Subsidiaries	1,500.00	1,500.00		
Repayment of debt	1,700.00	1,700.00		
For general corporate purposes	1,054.27	1,054.27		
Total	9,254.27	4,663.63		

Out of the total proceeds of ₹6,152.71 Lakhs, the Company has utilised ₹4,663.63 Lakhs for the intended purposes. The balance amount of ₹1,489.07 Lakhs is currently lying in the Company's bank account. In Addition to above the company would going to receive ₹3,101.57 Lakhs at the time of conversion of the warrants.

10 On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed the same & there is no material impact of these changes and to the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. The Company continues to monitor the finalisation of Central/ State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect (if any) on the basis of such developments as needed.

11 The figures for the second half of the financial year ended 31st March 2026 have been arrived at by deducting the unaudited financial results for the half year ended September 30, 2025 from the audited results for the full year ended 31st March 2026. These figures are not subjected to separate audit or limited review.

12 The figures of the previous period have been re-grouped or rearranged, wherever considered necessary.

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED


Hanskumar Shamji Shah
Managing Director
DIN - 00215972
Place: Mumbai
Date: 15th May, 2026

